What Happened?
Buffalo, NY-based Cleveland-Biolabs Promoted Yakov Kogan as Chief Executive Officer
About the Company
Cleveland Biolabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.
About the Person
Dr.Yakov Kogan has served as one of the Company’s directors since the Company’s inception in June 2003. Dr. Kogan was appointed Chief Executive Officer of Cleveland BioLabs in June 2012. Dr. Kogan also serves on the Boards of Directors of Incuron, LLC (since its formation in 2010) and Panacela Labs, LLC (since its formation in 2011). Prior to his appointment as CEO, Dr. Kogan served as interim Chief Executive Officer from January 2012 to June 2012, as Chief Operating Officer from 2008 to June 2012, as Secretary from 2006 to June 2012, and as Executive Vice President of Business Development from 2003 to 2008. During his tenure as Chief Operating Officer, Dr. Kogan built an infrastructure with more than 50 full-time employees and established and structured operations for two majority-owned subsidiaries, securing up to $41 million in project specific VC funding at highly attractive valuations. He was also responsible for securing nine new federal and state grants, totaling more than $36.5 million. While serving as Executive Vice President of Business Development for the Company, Dr. Kogan played a significant role in establishing operations, hiring senior operations staff and executing the Company's initial public offering on the NASDAQ exchange. Prior to founding Cleveland BioLabs, Dr. Kogan served as Director for Business Development at Integrated Genomics in Chicago, IL, where he was responsible for commercial sales and expansion of the company's capital base. Dr. Kogan closed several complex international contracts with new clients including Groupe Danone and Kyowa Hakko Kirin and expanded contracts with governmental research laboratories, representing more than one-third of total sales. Prior to his tenure in business development, Dr. Kogan worked as a Group Leader/Senior Scientist at Integrated Genomics and at ThermoGen, Inc. and as Research Associate at the University of Chicago, where he led the execution of several sophisticated genome sequencing projects. Dr. Kogan holds a Ph.D. degree in Molecular Biology from VNII Genetica, as well as an M.S. degree in Biology from Moscow State University and an MBA from the University of Chicago.
Info Source
News
Short Profile